Relative Bioavailability of Two Tablet Formulations of BGB-58067 and Food Effect in Healthy Adults

Phase 1, randomised, open-label trial of BGB-58067 in cancer (4 arms), sponsored by BeOne Medicines. Primary endpoints: Area under the Plasma Concentration-Time Curve from Time 0 to Infinity at 4 Days, Area under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration at 4 Days and 5 more. Started Jul 2026; status: recruiting.